Evaluation of the Efficacy and Safety of Vonoprazan in Patients with Nonerosive Gastroesophageal Reflux Disease: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study

详细信息    查看全文

• 作者：Yoshikazu Kinoshita ; MD ; PhD¹ ; ^{kinosita@med.shimane-u.ac.jp} ; Yuuichi Sakurai ; MPharm² ; Madoka Shiino ; MPharm² ; Kentaro Kudou ; MS² ; Akira Nishimura ; BSc ; MBA² ; Takuya Miyagi ; MD ; PhD³ ; Katsuhiko Iwakiri ; MD ; PhD⁴ ; Eiji Umegaki ; MD ; PhD⁵ ; Kiyoshi Ashida ; MD ; PhD⁶
• 关键词：gastroesophageal reflux ; heartburn ; NERD ; nonerosive gastroesophageal reflux disease ; potassium-competitive acid blockers ; vonoprazan
• 刊名：Current Therapeutic Research
• 出版年：2016
• 出版时间：2016
• 年：2016
• 卷：81-82
• 期：Complete
• 页码：1-7
• 全文大小：366 K
• 卷排序：81

文摘

More effective treatments are required for nonerosive reflux disease (NERD). Vonoprazan was not superior to placebo for median proportion of days without heartburn. The difference was significant for vonoprazan 20 mg vs placebo for NERD Grade M patients. Patients on vonoprazan reported significantly less severe heartburn vs placebo. Vonoprazan 20 mg may be effective for NERD, based on the per-protocol set.